Want to see DE:SBS full AI Analyst Report?

STRATEC Biomedical (SBS) Price & Analysis

6 Followers

SBS Stock Chart & Stats

€22.40

€0.10(0.34%)

At close: Jan 09 4:00 PM EST

€22.40

€0.10(0.34%)

Day’s Range― - ―

52-Week Range€16.30 - €33.10

Previous CloseN/A

Volume977.00

Average Volume (3M)15.55K

Market Cap

€230.96M

Enterprise Value€318.12M

Total Cash (Recent Filing)€23.74M

Total Debt (Recent Filing)€116.97M

Price to Earnings (P/E)―

Beta1.49

Next Earnings

Aug 14, 2026

EPS Estimate

0.24

Next Dividend Ex-DateN/A

Dividend Yield2.71%

Share Statistics

EPS (TTM)-0.27

Shares Outstanding12,157,841

10 Day Avg. Volume11,323

30 Day Avg. Volume15,548

Financial Highlights & Ratios

PEG Ratio11.11

Price to Book (P/B)1.15

Price to Sales (P/S)1.09

P/FCF Ratio-28.10

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€28.00

Price Target Upside25.00% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering3

EPS Forecast (FY)1.39

Revenue Forecast (FY)€263.75M

Bulls Say, Bears Say

Bulls Say

Balance Sheet & LeverageA solid equity base and materially reduced reported leverage provide durable financial flexibility. Lower debt levels increase the company's ability to fund seasonal H2 ramps, invest in product programs, and absorb cyclical revenue swings without immediate recapitalization, supporting multi‑year OEM commitments.

Improved Cash GenerationRecent rebound to positive operating and free cash flow reflects better working-capital management and reduces reliance on external funding. Durable cash generation—even if volatile—gives management room to invest in R&D and capex, sustain multiple program ramps, and buffer near-term profit volatility.

Systems / Instrument MomentumDouble-digit instrument growth indicates resilient OEM demand and expanding installed base. Instrument momentum underpins recurring aftermarket and consumables potential long term; as platforms scale, service and consumables can reaccelerate revenues and margins once mix normalizes.

Bears Say

Multi-year Revenue & Margin DeclineSustained top-line erosion and compressed gross/operating margins reduce operating leverage and threaten long‑term profitability targets. Continued revenue decline erodes pricing power and ROE, making it harder to achieve management’s 2028/2030 margin goals without structural mix or pricing improvements.

Consumables Order VisibilityHigh‑margin consumables are volatile yet critical to sustained margins and recurring revenue. Weakness and uncertain customer ordering patterns reduce predictability of cash flows and margin recovery; OEM concentration amplifies downside if key partners delay or optimize inventories further.

Elevated Inventory & Obsolescence RiskVery high inventories tie up capital and heighten write-down risk from obsolescence or last-time buys. This impairs free cash flow durability and may force margin‑dilutive clearance or increased provisioning, delaying normalization of working capital and pressuring returns until stock levels sustainably fall.

STRATEC Biomedical News

STRATEC Biomedical Balances Weak Q1 With Firm Outlook

STRATEC Biomedical (($DE:SBS)) has held its Q1 earnings call. Read on for the main highlights of the call....

2M ago

STRATEC Biomedical Balances Q1 Setback With Solid Outlook

STRATEC Biomedical (($DE:SBS)) has held its Q1 earnings call. Read on for the main highlights of the call....

2M ago

0RAR Upcoming Earnings Report: What to Expect?

STRATEC Biomedical (0RAR) is scheduled to report 4th quarter earnings on 03/26/2026. Regarding Q4 estimates, Wall Street analysts...

4M ago

STRATEC Biomedical’s Earnings Call: Mixed Outlook

STRATEC Biomedical (($DE:SBS)) has held its Q3 earnings call. Read on for the main highlights of the call....

8M ago

STRATEC Biomedical (0RAR) Unveils Dividend Details for Q3: Mark Your Calendar!

STRATEC Biomedical (LSE: 0RAR) has declared, under its dividend policy, a yearly cash dividend in the amount of...

1y ago

0RAR Earnings this Week: How Will it Perform?

STRATEC Biomedical (0RAR) is scheduled to report 3rd quarter earnings on 10/25/2024, before the market opens. Regarding Q3...

2y ago

SBS FAQ

What was STRATEC Biomedical AG’s price range in the past 12 months?

STRATEC Biomedical AG lowest stock price was €16.30 and its highest was €33.10 in the past 12 months.

What is STRATEC Biomedical AG’s market cap?

STRATEC Biomedical AG’s market cap is €230.96M.

When is STRATEC Biomedical AG’s upcoming earnings report date?

STRATEC Biomedical AG’s upcoming earnings report date is Aug 14, 2026 which is in 32 days.

How were STRATEC Biomedical AG’s earnings last quarter?

Currently, no data Available

Is STRATEC Biomedical AG overvalued?

According to Wall Street analysts STRATEC Biomedical AG’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does STRATEC Biomedical AG pay dividends?

STRATEC Biomedical AG pays a Annually dividend of €0.6 which represents an annual dividend yield of 2.71%. See more information on STRATEC Biomedical AG dividends here

What is STRATEC Biomedical AG’s EPS estimate?

STRATEC Biomedical AG’s EPS estimate is 0.24.

How many shares outstanding does STRATEC Biomedical AG have?

STRATEC Biomedical AG has 12,157,841 shares outstanding.

What happened to STRATEC Biomedical AG’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of STRATEC Biomedical AG?

Currently, no hedge funds are holding shares in DE:SBS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

STRATEC Biomedical Stock Smart Score

Neutral

Analyst Consensus

Moderate Buy

Average Price Target:
€28.00 (25.00% Upside)

Technicals

Top Smart Score Stocks >

Company Description

STRATEC Biomedical AG

Established in 1979 and headquartered in Birkenfeld, Germany, Stratec SE (previously known as STRATEC Biomedical AG until its name change in December 2018) specializes in the development and manufacturing of cutting-edge automation and instrumentation systems. The company caters to the in-vitro diagnostics and life sciences sectors, operating across Germany, the European Union, and globally. Its business is divided into three primary segments: Instrumentation, Diatron, and Smart Consumables. The Instrumentation segment focuses on designing and fabricating automated analytical systems, along with necessary spare parts and supplies, for customers in clinical diagnostics and biotechnology. The Diatron segment provides a suite of systems, components, disposables, and assays for lower-volume hematology and clinical chemistry applications. Finally, the Smart Consumables segment is dedicated to engineering and producing intelligent consumables for the diagnostics, life sciences, and medical technology industries.

STRATEC Biomedical (SBS) Earnings & Revenues

Historic Earnings Reports

SBS Stock 12 Month Forecast

Average Price Target

€28.00

▲(25.00% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"15":"€15","38":"€38","20.75":"€20.8","26.5":"€26.5","32.25":"€32.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":37,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€37.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":28,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€28.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€21.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[15,20.75,26.5,32.25,38],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.6,19.092307692307692,20.584615384615386,22.076923076923077,23.56923076923077,25.06153846153846,26.553846153846152,28.046153846153846,29.53846153846154,31.03076923076923,32.52307692307692,34.01538461538462,35.50769230769231,{"y":37,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.6,18.400000000000002,19.200000000000003,20,20.8,21.6,22.400000000000002,23.200000000000003,24,24.8,25.6,26.4,27.200000000000003,{"y":28,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.6,17.861538461538462,18.123076923076923,18.384615384615387,18.646153846153847,18.907692307692308,19.16923076923077,19.430769230769233,19.692307692307693,19.953846153846154,20.215384615384615,20.47692307692308,20.73846153846154,{"y":21,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":26.097,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.856,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.518,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.336,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.714,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.941,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.7,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.265,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.96,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.915,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.012,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.528,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.6,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >